Decheng Capital LLC Buys Shares of 40,000 BioNTech SE (NASDAQ:BNTX)

Decheng Capital LLC acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 40,000 shares of the company’s stock, valued at approximately $4,558,000. BioNTech comprises about 1.0% of Decheng Capital LLC’s investment portfolio, making the stock its 20th biggest position.

Other hedge funds have also made changes to their positions in the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of BioNTech in the fourth quarter worth $14,091,000. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of BioNTech by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 281,412 shares of the company’s stock worth $32,067,000 after purchasing an additional 5,581 shares during the period. Voya Investment Management LLC lifted its position in BioNTech by 14.5% during the fourth quarter. Voya Investment Management LLC now owns 27,870 shares of the company’s stock worth $3,176,000 after buying an additional 3,520 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in shares of BioNTech during the 4th quarter valued at about $786,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in BioNTech during the fourth quarter worth approximately $6,078,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 15.4 %

Shares of BioNTech stock opened at $102.02 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market cap of $24.48 billion, a price-to-earnings ratio of -48.58 and a beta of 1.07. The stock has a 50-day simple moving average of $101.72 and a 200-day simple moving average of $110.64. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the company posted $1.90 earnings per share. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, equities research analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. BMO Capital Markets upped their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup started coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target for the company. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Finally, Morgan Stanley cut their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.